Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bong who wrote (1161)	11/1/1999 12:48:00 PM
From: Pseudo Biologist	Respond to of 1686

Thanks for this information, very interesting. Thanks also to cm for sharing the Goldman report. Given Biogen's silence on the Antova problems, other than acknowledgment of their existence, every bit of informed speculation helps. PB

To: Mark Bong who wrote (1161)	11/2/1999 8:53:00 AM
From: Harold Engstrom	Read Replies (2) \| Respond to of 1686

Mark, per our conversation last night, here is a partial list of companies and drug candidates (besides Biogen and Amevive) pursuing psoraiasis indication. The database I use is slightly dated and some of these compounds may be further along or may have halted. There are certainly more companies and compounds chasing psoraisis than are shown below: Protein Design Labs: Zenapax (PIIb), SMART anti-CD3 (PII) IDEC: IDEC-114 (PII) CellGate: PI OSI Pharmaceuticals: preclinical Corixa: P-Vac, (PII) QLT: Visudyne (PIIb) Ligand: Tagretin (PII), Ontak (PII) Vertex: VX-497 (PII)